









































Pa
ge

 
1



Pa
ge

 
9

American Journal of  
Chemistry and Pharmacy (AJCP)

Diabetes Mellitus Control and Chronic Kidney Disease
Safaa Mohamed Matarid1*

Volume 2 Issue 2, Year 2023
ISSN: 2834-0116 (Online)

DOI: https://doi.org/10.54536/ajcp.v2i2.1612
https://journals.e-palli.com/home/index.php/ajcp

Article Information ABSTRACT

Received: April 16, 2023

Accepted: May 08, 2023

Published: May 13, 2023

Chronic kidney disease (CKD) is the rampant onset of  diabetes and related complications; 
chronic kidney disorders and end-stage renal disease are progressing in more than 10% of  
the world population and mostly affect the elderly, women, minorities and patients with 
diabetes and hypersensitivity. The early stages of  CKD are typically quiet; thus, many people 
are unaware they have the condition. Data for this review was gathered from Google Scholar, 
Scopus, PubMed, Elsevier, Cochrane, Sage, Medline, and Web of  Science. Studies were 
selected from 2018-2023, using keywords such as Diabetes mellitus management, chronic 
kidney disease, microalbuminuria, target time in range, impaired fasting glucose, management 
ways, lifestyle modification, medication treatment, and diet control.  Although blood glucose 
levels are too unpredictable to provide a reliable evaluation, measures reflecting long-term 
glycemic load are used instead. The results gathered after the review suggests that optimal 
glycemic control along with lifestyle medication and diet control contributes to better 
outcomes in individuals with DM, particularly for microvascular damage. While, HbA1c 
is the most well-known glycemic biomarker of  long-term glycemic management. This 
suggests that effective treatments are progressing on progression.This review has discussed 
different CKD management parameters; the authors have discussed the disease’s treatment 
criteria and protocols, such as pharmacological therapies, lifestyle modifications, physical 
activities and insulin therapy and concluded that to avoid CKD, it’s critical to concentrate on 
underlying problems including hyperglycemia, hypertension, microalbuminuria, sedentary 
behaviour, and smoking. The occurrence of  CKD can be reduced with changes in lifestyle, 
such as increased physical activity, nutritious food, and water consumption.

Keywords
Chronic Kidney Disease, 
End Stage Renal 
Stage, Albuminuria, 
Pharmacological Therapies

1 Department of  Internal Medicine, Mediclinic Al Ain Hospital, heikh Khalifa Bin Zayed St - next to Choithrams Supermarket, Abu  
  Dhabi - United Arab Emirates 
* Corresponding author’s e-mail: SafaaMatarid12@outlook.com

INTRODUCTION
Diabetes Mellitus is the most common and prevalent 
disease worldwide, affecting approximately 29.2% of  
people per year in the United States; while 537 million 
people around the world are reported to have diabetes, 
this number is expected to grow by half  a billion by the 
year 2040 (Association, 2022; IDF, 2021; Prevention, 
2020). Diabetes mellitus is a progressive metabolic 
disease that is implanted by the constant condition of  
hyperglycemia. Diabetes is prompted by the action 
of  insulin that decreases insulin production, insulin 
resistance, or both (Goyal & Jialal, 2018). Hyperglycemia 
is a recognised marker for the onset and development 
of  both DPN and CKD. This lethal disease causes more 
lethal macrovascular comorbidities such as cardiovascular 
diseases, diabetic peripheral neuropathy, Diabetic 
retinopathy and CKD, leading to increased mortality 
rates and decreased quality of  life (Cole & Florez, 2020). 
During the 1st century AD, diabetes was considered a 
urinary tract disease or a kidney disease due to its high 
urine flow. Diabetes affects the kidneys primarily due to 
a deficiency in their retentive properties. Diabetes-related 
urine has a sweet flavour because it contains nutrients 
and water that have been ingested but not broken down 
(Eknoyan & Nagy, 2005). The sweetness of  diabetic urine 
was the initial indicator used by Thomas Willis in 1674 to 
distinguish diabetes from other types of  polyuria, and he 
proposed that the sweet flavour initially manifests in the 

blood(Sutherland & Gruessner, 2020). A century later, 
Matthew Dobson demonstrated that the sweet flavour 
of  urine was caused by sugar and that blood sugar had 
both paved and followed it. Although diabetes was later 
linked to higher blood sugar levels, sugar in the urine was 
still accredited to the kidneys’ reduced ability for retentive 
functioning (Porta, 2020). 
Diabetic kidney disease or CKD happened by diabetes 
or diabetic nephropathy is the most typical onset of  
diabetes mellitus and also the major reason of  end-stage 
renal disorder (ERSD). Diabetic kidney disease (DN) is 
characterised by hyperfiltration and albuminuria, followed 
by a loss of  renal function. It can show in various ways, 
particularly in individuals with T2DM who may also 
have peripheral vascular and other glomerular/tubular 
diseases (Sagoo & Gnudi, 2020). CKD is reported to 
affect approximately 8 to 16 % population globally, and 
around 30-50 % of  cases of  end-stage renal disorder 
are considered to be preceded by diabetic kidney disease 
(Chen et al., 2019; Copur et al., 2020). The incidence 
of  classic diabetic nephropathy in Type 1 diabetes has 
decreased from 25% to 10-15% with blood pressure 
management and more use of  an angiotensin converter. 
The overall incidence of  diabetes will rise from 6% to 
10% of  adults in the coming years, leading to more cases 
of  Type 2 diabetes and kidney disease (Winocour, 2018). 
CKD is recognised by a biomarker called micro-albumin, 
which is present in urine. The higher levels of  micro-

https://doi.org/10.54536/ajcp.v2i2.1612
https://journals.e-palli.com/home/index.php/ajcp


Pa
ge

 
9

https://journals.e-palli.com/home/index.php/ajcp

Am. J. Chem. Pharm. 2(2) 9-14, 2023

albumin in urine indicate the presence of  a disorder. At 
the same time, albuminuria is a condition of  having too 
much protein in the urine, resulting in kidney damage 
(Raja et al., 2021). Diabetes and CKD together increase 
the probability of  amputations of  the lower limbs by two 
to six times compared to diabetes alone in patients with 
CKD (Rodrigues et al., 2022). 

LITERATURE REVIEW
Progression of  Micro and Macro- Albuminuria
Microalbuminuria is caused by a malfunction of  the 
glomerular basement membrane (GBM). This enzyme 
is inhibited by insufficient blood sugar management, 
which lowers the negative charge on GBM and causes 
extra albumin to leak out. It is linked to type 1 and type 
2 diabetic individuals (Prasad & Tikaria, 2022). In those 
with type 1 diabetes, microalbuminuria is 6% prevalent 
after three years but 41% common after five. Type 2 
diabetes affects 20% to 25% of  diabetic paeople (Prasad 
& Tikaria, 2022). A decreased glomerular filtration rate, 
increased microalbuminuria, or both characterise diabetic 
nephropathy or DKD. Laboratory tests are used to 
diagnose CKD, most frequently by estimating glomerular 
filtration rate (GFR) using a filtration marker like serum 
creatinine or cystatin C. The albumin or protein in the 
urine can be determined using several formulas or other 
methods (Kovesdy, 2022). Microalbuminuria, defined by 
urine albumin excretion of  30-300 mg/day, is thought to 
be a predictor of  DKD. It is regarded as an adjustable 
problem for the progression of  renal disease to its 
terminal stages (Hussain et al., 2020). The progression of  
microalbuminuria can vary depending on the underlying 
cause and individual factors such as age, blood pressure, 
and blood sugar control (Oshima et al., 2021). However, 
in general, the progression of  microalbuminuria can be 
divided into three stages:

1. Early stage: In the early stages of  microalbuminuria, 
the albumin in the urine is slightly elevated but still within 
a normal range. This stage may not cause symptoms, and 
kidney function may still be normal (Parving et al., 2015).

2. Moderate stage: As microalbuminuria progresses, the 
albumin in the urine elevates, and kidney function may 
decline. This stage is often characterised by hypertension, 
an elevation in albuminuria, and a decline in the glomerular 
filtration rate (GFR) (Webster et al., 2017).

3. Severe stage: In the severe stage of  microalbuminuria, 
there is a significant elevation in the amount of  albumin in 
the urine, and kidney function is severely impaired. At this 
stage, patients may experience fatigue, weakness, leg swelling, 
and difficulty concentrating (Romagnani et al., 2017).
It is essential to diagnose and treat microalbuminuria 
in the early stages to prevent the progression of  kidney 
disease. Treatment may involve medication to control 
blood pressure and blood sugar, lifestyle changes such 
as a healthy diet and exercise, and regular monitoring 
of  kidney function. If  left untreated, microalbuminuria 
can progress to macroalbuminuria, which is the presence 
of  large amounts of  albumin in the urine (Persson & 

Rossing, 2018). Macro albuminuria is a more advanced 
stage of  kidney disease and is usually acknowledged with 
a degradation in kidney function and an increased risk of  
cardiovascular disease (Persson & Rossing, 2018).

Target Time in Range and Hba1c
The A1C test, blood glucose monitoring (BGM), and 
continuous glucose monitoring (CGM) are all used to 
examine glycemic control. The A1C is the commonly 
used biomarker for assessing blood glucose control in 
diabetics, as it decreases both long-term and short-term 
macrovascular disease and long-term microvascular 
consequences (Wright et al., 2020). Whereas time in range 
(TIR) refers to the amount of  time that a person with 
diabetes spends within a target range of  blood glucose 
levels (Advani, 2020). For diabetic people, maintaining 
blood glucose levels within a target range is important for 
preventing complications such as nerve damage, kidney 
disease, and cardiovascular disease (Advani, 2020). TIR is 
useful for monitoring blood glucose levels and assessing 
how well diabetes management strategies work (Mayeda et 
al., 2020). The target range for TIR can vary depending on 
the individual, but a common target range is between 70 
and 180 mg/dL (Beck et al., 2019). TIR can be measured 
using continuous glucose monitoring (CGM) devices, 
which provide real-time glucose readings throughout the 
day and night (Gabbay et al., 2020). HbA1C and TIR are 
two essential diabetes management metrics. However, 
they serve different functions (Lu et al., 2020). TIR is 
used to monitor short-term changes in blood glucose 
levels and evaluate the efficacy of  diabetes management 
techniques, while HbA1C is used to examine long-term 
glycemic control and assist with treatment options (Yoo 
& Kim, 2020). However, a correlation exists between 
HbA1C and TIR due to the same variables impacting 
blood sugar levels, such as food, exercise, and medication 
use (Vigersky & McMahon, 2019). A lower HbA1C 
indicates better long-term glycemic management and 
is more common in patients with higher TIR levels. 
Generally, a higher TIR is associated with better diabetes 
management and lower risk of  complications (Shah et al., 
2021). Through TIR and HbA1C metrics, diabetes can 
be managed, preventing the chances of  CKD and other 
diabetes-related complications.

Prevention at the Level of  Impaired Fasting Glucose 
and Prediabetes
Prevention of  CKD and diabetes can only be done by 
managing the disease at impaired fasting glucose (IFG) 
and prediabetes levels. Impaired fasting blood sugar (IFG) 
is a pre-diabetic condition linked to a relatively elevated 
probability of  developing diabetes2 (Yu et al., 2020). Early 
identification of  prediabetes and individualised therapy 
are required to effectively manage this steadily increasing 
diabetic population. IFG is a significant indicator of  
diabetes and its comorbidities (Yu et al., 2020). Consistently 
high blood sugar levels can cause heart problems, diabetic 
nephropathy, retinopathy, neuropathy, and increased 

https://journals.e-palli.com/home/index.php/ajcp


Pa
ge

 
10

https://journals.e-palli.com/home/index.php/ajcp

Am. J. Chem. Pharm. 2(2) 9-14, 2023

mortality (Tong & Adler, 2018). Impaired fasting glucose 
(IFG) and prediabetes are conditions that can highten the 
probability of  developing CKD and other issues, such as 
cardiovascular disease (Kim et al., 2020). Management of  
these conditions typically involves lifestyle modifications 
and medication, as appropriate, to improve glucose 
control and reduce the risk of  complications.

1. Lifestyle modifications: A nutritious diet, frequent 
exercise, and weight management are examples of  
lifestyle changes. Frequent exercises, like brisk walking or 
cycling, can also improve glucose control and lower the 
risk of  comorbidities (Beulens et al., 2020). 

2. Medication: Sometimes, medication may be 
prescribed to improve glucose control. Metformin is 
commonly used to treat prediabetes and IFG (Beulens 
et al., 2020). 

3. Blood pressure management: High blood pressure 
increases CKD risk and can accelerate the development of  
IFG and prediabetes. Periodic blood pressure assessments 
are recommended, and medication for hypertension can 
also be provided when necessary. (Ohishi, 2018)

4. Regular monitoring: Regular blood tests can help 
to monitor glycemic control and kidney function. This 
may include a blood test called the estimated glomerular 
filtration rate (eGFR) to assess kidney function (Miller 
& Jones, 2018). Overall, early identification and 
management of  prediabetes and IFG are important to 
prevent the development or progression of  CKD and 
other complications.

METHODOLOGY
To indicate the development of  CKD into end-stage 
renal failure by managing diabetes mellitus, several recent 
studies, review articles, prospective studies, cross-sectional 
studies, and literature reviews, all published and peer-
reviewed articles, were searched and considered. The area 
of  search was based on how effective the management of  
debates mellitus is in preventing chronic kidney disease, 
microalbuminuria and other comorbidities. Data was 
gathered from different search engines and databases such 
as; Google Scholar, Scopus, PubMed, Elsevier, Cochrane, 
Sage, Medline, and Web of  Science, Elsevier.
Numerous studies were selected from 2018-2023, using the 
keywords Diabetes mellitus management, chronic kidney 
disease, microalbuminuria, target time in range, Impaired 
fasting glucose, management ways lifestyle modification, 
and medication treatment, Diet Control. The full texts of  
the retrieved articles were made accessible.
This article is a review. Thus not all information on 
the prevention of  CKD by management of  diabetes 
mellitus has been provided are contained in this. We 
have included observational studies and all significant, 
pertinent big trials to highlight the overall conclusions. 
Although we tried to incorporate the largest and most 
pertinent research, it is important to remember that the 
tiny, hopeful observational studies were likely chosen due 
to publication bias.

DISCUSSION
Occurrence of  CKD in T2DM 
For populations with type 2 diabetes or a mix of  diabetes 
types, the yearly rate of  albuminuria is typically around 
8%, while for groups with type 1 diabetes, it ranges from 
2% to 3%. Regardless of  the type of  diabetes, low eGFR 
occurs between 2% and 4% of  the time. However, due 
to significant demographic estimate variability, combined 
CKD incidence rates are impractical (Koye et al., 2018).
Microalbuminuria and albuminuria occur about 2-3% 
of  the time in Type 1 diabetes and about 8% in Type 2 
diabetes or mixed diabetes types. The yearly occurrence 
of  eGFR 60 ml/min/1.73 m2 is between 2 and 4 per 
cent. There was a relatively slight difference in prevalence 
rates within a single category of  kidney illness, despite 
the considerable variation in methodologies and research 
design (Koye et al., 2017). Various studies have determined 
that an elevation in the occurrence rates of  diabetes 
and hypertension increases the probability of  CKD. 
However, according to a population-based cohort study, 
it was reported that diabetes and high blood pressure do 
not have an alliance when it comes to the incidence of  
chronic kidney disease (Erfanpoor et al., 2021). Prevalence 
of  CKD in all phases varies globally, with 1.7% in China, 
3.1% in Canada, 6.7% in the US and 5.8% in Australia. 
In Europe, 2.3% in Germany, 8.2% in Finland, 9.2% in 
Spain and 5.2% in England (Romagnani et al., 2017).

Risk Factors
CKD is a progressive problem of  diabetes, particularly 
in people with poorly controlled blood glucose levels. 
Several Indisputable risk factors are crucial for diagnosing, 
treating and managing CKD in diabetes (Kazancioğlu, 
2013). The risk factors for CKD in diabetes can be 
categorised as modifiable and non-modifiable. To stop or 
slow the start and advancement of  CKD in patients with 
diabetes, early detection and management of  these risk 
factors are crucial (Hannan et al., 2021). This may include 
regular monitoring of  blood glucose and blood pressure 
levels, lifestyle modifications such as healthy eating and 
regular physical activity, and medication as appropriate. 
Non-modifiable factors may include Genetics, Male, age, 

Table 1: Modifiable and un-modifiable risk factors of  
CKD 
Non- Modifiable Risk 
Factors

Modifiable Risk Factors

Genetics factor Hypertension
Male Sex Poor Glycemic control
Age at onset of  diabetes Lipid abnormalities
Duration of  diabetes Smoking
Family History Obesity

Metabolic syndrome
Vitamin D deficiency and 
Salt Intake
Gestational Diabetes

https://journals.e-palli.com/home/index.php/ajcp


Pa
ge

 
11

https://journals.e-palli.com/home/index.php/ajcp

Am. J. Chem. Pharm. 2(2) 9-14, 2023

family history, the onset of  diabetes etc., while modifiable 
factors contain hypertension, poor glycemic control, 
insulin resistance, smoking, metabolic syndrome, vitamin 
D deficiency etc. (Hannan et al., 2021; Koye et al., 2018; 
Kurzhagen et al., 2020). 
Elevated blood glucose levels can damage the kidney’s 
small blood vessels, leading to CKD. Hypertension or 
high blood pressure also damages the blood vessels and 
contributes to the risk of  causing CKD (Kurzhagen et al., 
2020). CKD also depends upon the duration of  diabetes 
onset; according to the reported studies that a longer 
duration of  diabetes can increase the risk of  developing 
CKD in patients (Hannan et al., 2021). Smoking is 
injurious on many levels; it damages the lungs and 
kidneys and worsens glucose control in diabetic people 
(Kazancioğlu, 2013). 

Prevention of  CKD
CKD can be prevented or delayed by taking measures 
to maintain healthy kidneys. Maintaining underlying 
conditions, quitting smoking, eating healthy foods, 
exercising regularly and drinking enough water can help 
stabilise CKD and diabetes. Other than these preventions, 
insulin therapies play a vital role in managing CKD, while 
some medications are widely used to prevent mortality. 
Some interventions to manage and prevent CKD are 
explained in this review.

Lifestyle Modification
Healthy dietary intake and weight are vital in reducing 
most chronic diseases, including renal end-stage diseases. 
Dietary and lifestyle modifications have been shown to 
help treat diabetes and improve glycemic control. When 
a patient’s eGFR drops below 60 mL/min/1.73 m2, it is 
recommended that they seek the advice of  a nutritionist 
to optimise their diet to improve hyperglycemia and 
ensure they are getting enough protein, potassium, and 
phosphorus to prevent the condition from worsening 
(Williams, 2017). Nutrition is essential for people with 
diabetic kidney disease to maintain an equilibrium of  
salt, potassium, phosphorus, protein, carbohydrate, and 
unhealthy fat intake. Patients who are overweight or obese 
should reduce their weight and improve their exercise, as 
cardiac stress testing is necessary (Hahr & Molitch, 2015). 
According to the Kidney Disease Outcomes Quality 
Initiative (KDOQI) of  the National Kidney Foundation, 
following a low-protein diet (LPD) can help CKD 
patients live better lives and decrease the progression of  
ESRD (Alkhatib et al., 2023). It has been proven that diets 
high in fruits and vegetables and low in saturated fat can 
effectively lower blood pressure. These diets also limit salt 
intake (Bello et al., 2005). Moreover, Cessation of  smoking 
also helps in maintaining healthy kidney 
Pharmacological Management
Intense care of  glycemic control decreases the risk of  
microalbuminuria and macroalbuminuria. According 
to a report, every increase in systolic blood pressure 
in the general population above 115 mm Hg has been 

said to double the risk of  cardiovascular disease (CVD). 
Management of  hypertension is essential to prevent 
albuminuria/proteinuria and the ensuing development 
of  CKD in both diabetic and non-diabetic individuals. 
Pre-hypertensive conditions, lower blood pressure levels 
in the general population, and more active blood pressure 
lowering in patients with hypertension and underlying 
CKD are essential (Bello et al., 2005). Standardising a 
distinct ratio for every patient is crucial for blood glucose 
management and CKD prevention. Maintaining a blood 
pressure (BP) less than 130/80 in DKD patients is the 
typical aim advised by the National Kidney Foundation; 
nevertheless, there is considerable debate around this 
recommendation (Williams, 2017). Due to their ability 
to preserve the kidneys, ACE inhibitors and ARBs are 
typically regarded as first-line treatments for hypertension 
in diabetic people. Patients with diabetes mellitus have 
been shown to benefit from ACE inhibitors in terms of  
kidney, heart, and, to a lesser extent, eye and peripheral 
nerve function. These positive outcomes result from 
angiotensin II’s hemodynamic and tissular actions being 
inhibited (Williams, 2017).

Medications
Some treatments suggested by healthcare professionals 
are first-line care for the prevention of  CKD, such as 
metformin (Betônico et al., 2016; Beulens et al., 2020). 
This medication has been advised to patients for years. 
The mechanism of  this drug is to decrease the production 
of  hepatic glucose, improve insulin tolerance, lowering 
impaired fasting glucose and plasma glucose. Although 
metformin is the most common drug to prevent and 
manage CKD, it still is contradictory to its nature because 
metformin excretes through the renal system and the 
emergence of  lactic acidosis, which is one of  its most 
serious drawbacks but only occurs in about 5 cases per 
100,000 patient-years of  patients on average. Metformin 
can be used to treat type 2 diabetes (T2DM) up to a GFR 
of  30 mL/min/1.73 m2, with a lower dose indicated at 
45 mL/min/1.73 m2 (current UK guidelines) (Betônico 
et al., 2016). 
Sulfonylureas (SUs) encourage pancreatic b cells to secrete 
endogenous insulin, leading to hypoglycemia, alcohol 
abuse, hepatic dysfunction, heart failure, malnutrition, 
advanced age, and interactions with other medications 
that displace SUs from their plasma protein-binding sites 
(Seino et al., 2016). This is due to accumulating one or 
more of  these medications’ metabolites, increasing the 
risk of  hypoglycemia. Other medications help decrease 
the incidence of  CKD in diabetes, such as glinides, 
Alpha-glucosidase inhibitors, glitazones, and dipeptidyl 
peptidase 4 inhibitors (Seino et al., 2016). 

Insulin Therapy
The kidney is crucial in removing insulin from the 
bloodstream through two different mechanisms. In the 
initial stage, insulin is filtered by the glomerulus and 
then taken up by proximal tubular cells via endocytosis 

https://journals.e-palli.com/home/index.php/ajcp


Pa
ge

 
12

https://journals.e-palli.com/home/index.php/ajcp

Am. J. Chem. Pharm. 2(2) 9-14, 2023

(Peruchetti et al., 2021). The second process includes 
insulin attaching to the contra luminal tubular membrane 
of  cells and diffusing through peritubular capillaries. 
Lysosomes transport insulin, broken down into 
amino acids and diffused into the peritubular arteries. 
Insulin clearance declines when renal failure worsens, 
necessitating a dosage reduction to prevent hypoglycemia 
(Peruchetti et al., 2021). This decrease in insulin clearance 
is initially offset by a rise in proximal tubular cells’ insulin 
absorption, and it is also linked to an increase in insulin 
resistance. Muscle tissue is the predominant source 
of  IR in CKD, occurring mostly at the extremities. In 
individuals with ESRD, hepatic glucose production is 
not elevated and repressed in response to insulin, and IR 
may not result in a proportional rise in insulin secretion 
(Gburek et al., 2021).

Lipid Metabolism
Dysregulation of  lipid metabolism leads to higher levels 
of  triglycerides, oxidised lipoproteins, and lower levels 
of  HDL cholesterol in chronic renal disease and ESRD. 
Advanced CKD or ESRD patients have a distinctive lipid 
pattern that includes hypertriglyceridemia, low HDL 
cholesterol, and normal LDL cholesterol levels (Dincer 
et al., 2019). In the general population, there is a clear 
correlation between LDL cholesterol and atherosclerotic 
events, but in patients with ESRD, LDL cholesterol has a 
flat or weakly positive correlation with mortality at levels 
above the average and a negative correlation with these 
outcomes at levels below the average. Reducing LDL 
cholesterol helps prevent serious atherosclerotic events 
in people with CKD and kidney transplants but not for 
people who need dialysis (Ferro et al., 2018). 

Limitations and Strengths
1. The management and treatments discussed in this 

review do not guarantee the reversal of  the disease.
2. Several participants were not tested in this review; 

the review is based on factual data.
3. The most coherent risk factor of  mortality due to 

CKD is increasing age, which has not been extensively 
discussed.

4. The biggest strength of  this review is that very 
generalised terms have been used in searching strategies 
to combat vast unrelated data.

5. This review is based on scientifically proven facts.

CONCLUSION
In conclusion of  this review, Diabetes mellitus is the 
most common and biggest risk factor for the occurrence 
of  CKD and ESRD. It is advised to maintain and 
focus on the underlying conditions that result in CKD 
over time to prevent the disease. These conditions 
include hyperglycemia, hypertension, microalbuminuria, 
sedentary lifestyle, smoking, etc. These underlying 
conditions may turn into symptoms and eventually 
convert into morbidity. Changes in lifestyle, such as 
healthy eating, regular physical activity, and intake of  

advised ml of  water in addition to some medications and 
therapies, can altogether increase improvement rates of  
CKD incidence. Further future studies need to be done 
to combat the disease better. 

REFERENCES
Advani, A. (2020). Positioning time in range in diabetes 

management. Diabetologia, 63(2), 242-252. 
Alkhatib, L., Diaz, L. A. V., Varma, S., Chowdhary, A., 

Bapat, P., Pan, H., Kukreja, G., Palabindela, P., Selvam, 
S. A., & Kalra, K. (2023). Lifestyle modifications and 
nutritional and therapeutic interventions in delaying 
the progression of  chronic kidney disease: A review. 
Cureus, 15(2). 

Association, A. D. (2022). Statistics about Diabetes. American 
Diabetes Association https://diabetes.org/about-us/
statistics/about-diabetes#:~:text=Prevalence%20in%20
seniors%3A%20The%20percentage,diagnosed%20
with%20diabetes%20every%20year. 

Beck, R. W., Bergenstal, R. M., Cheng, P., Kollman, 
C., Carlson, A. L., Johnson, M. L., & Rodbard, D. 
(2019). The relationships between time in range, 
hyperglycemia metrics, and HbA1c. Journal of  Diabetes 
Science and Technology, 13(4), 614-626. 

Bello, A. K., Nwankwo, E., & El Nahas, A. M. (2005). 
Prevention of  chronic kidney disease: a global 
challenge. Kidney International, 68, 11-17. 

Betônico, C. C., Titan, S. M., Correa-Giannella, M. L. 
C., Nery, M., & Queiroz, M. (2016). Management 
of  diabetes mellitus in individuals with chronic 
kidney disease: therapeutic perspectives and glycemic 
control. Clinics, 71, 47-53. 

Beulens, J., Rutters, F., Rydén, L., Schnell, O., 
Mellbin, L., Hart, H., & Vos, R. (2020). Risk and 
management of  pre-diabetes. European Journal 
of  Preventive Cardiology, 26(2l), 47-54. https://doi.
org/10.1177/2047487319880041 

Chen, T. K., Knicely, D. H., & Grams, M. E. (2019). 
Chronic kidney disease diagnosis and management: a 
review. Jama, 322(13), 1294-1304. 

Cole, J. B., & Florez, J. C. (2020). Genetics of  diabetes 
mellitus and diabetes complications. Nature Reviews 
Nephrology, 16(7), 377-390. 

Copur, S., Onal, E. M., Afsar, B., Ortiz, A., van Raalte, 
D. H., Cherney, D. Z., Rossing, P., & Kanbay, M. 
(2020). Diabetes mellitus in chronic kidney disease: 
biomarkers beyond HbA1c to estimate glycemic 
control and diabetes-dependent morbidity and 
mortality. Journal of  Diabetes and its Complications, 
34(11), 107707. 

Dincer, N., Dagel, T., Afsar, B., Covic, A., Ortiz, A., & 
Kanbay, M. (2019). The effect of  chronic kidney 
disease on lipid metabolism. International Urology and 
Nephrology, 51, 265-277. 

Eknoyan, G., & Nagy, J. (2005). A history of  diabetes 
mellitus or how a disease of  the kidneys evolved into 
kidney disease. Advances in chronic kidney disease, 12(2), 
223-229. 

https://journals.e-palli.com/home/index.php/ajcp


Pa
ge

 
13

https://journals.e-palli.com/home/index.php/ajcp

Am. J. Chem. Pharm. 2(2) 9-14, 2023

Erfanpoor, S., Etemad, K., Kazempour, S., Hadaegh, 
F., Hasani, J., Azizi, F., Parizadeh, D., & Khalili, D. 
(2021). Diabetes, Hypertension, and Incidence of  
Chronic Kidney Disease: Is There any Multiplicative 
or Additive Interaction? Int. J. Endocrinol Metab, 19(1), 
e101061. https://doi.org/10.5812/ijem.101061 

Ferro, C. J., Mark, P. B., Kanbay, M., Sarafidis, P., Heine, 
G. H., Rossignol, P., Massy, Z. A., Mallamaci, F., 
Valdivielso, J. M., Malyszko, J., Verhaar, M. C., Ekart, 
R., Vanholder, R., London, G., Ortiz, A., & Zoccali, 
C. (2018). Lipid management in patients with chronic 
kidney disease. Nature reviews nephrology, 14(12), 727-
749. https://doi.org/10.1038/s41581-018-0072-9 

Gabbay, M. A. L., Rodacki, M., Calliari, L. E., Vianna, A. 
G. D., Krakauer, M., Pinto, M. S., Reis, J. S., Puñales, 
M., Miranda, L. G., Ramalho, A. C., Franco, D. R., 
& Pedrosa, H. P. C. (2020). Time in the range: a new 
parameter to evaluate blood glucose control in patients 
with diabetes. Diabetology & Metabolic Syndrome, 12(1), 
22. https://doi.org/10.1186/s13098-020-00529-z 

Gburek, J., Konopska, B., & Gołąb, K. (2021). Renal 
Handling of  Albumin—From Early Findings to 
Current Concepts. International Journal of  Molecular 
Sciences, 22(11), 5809. 

Goyal, R., & Jialal, I. (2018). Diabetes mellitus type 2. 
Hahr, A. J., & Molitch, M. E. (2015). Management of  

diabetes mellitus in patients with chronic kidney 
disease. Clinical Diabetes and Endocrinology, 1(1), 1-9. 

Hannan, M., Ansari, S., Meza, N., Anderson, A. H., 
Srivastava, A., Waikar, S., Charleston, J., Weir, M. R., 
Taliercio, J., & Horwitz, E. (2021). Risk factors for 
CKD progression: an overview of  findings from the 
CRIC study. Clinical Journal of  the American Society of  
Nephrology, 16(4), 648-659. 

Hussain, S., Habib, A., Hussain, M. S., & Najmi, A. K. 
(2020). Potential biomarkers for early detection of  
diabetic kidney disease. Diabetes Research and Clinical 
Practice, 161, 108082. https://doi.org/https://doi.
org/10.1016/j.diabres.2020.108082 

IDF. (2021). IDF Diabetes Atlas 2021. https://
diabetesatlas.org/atlas/tenth-edition/

Kazancioğlu, R. (2013). Risk factors for chronic kidney 
disease: an update. Kidney international supplements, 3(4), 
368-371. 

Kim, H., Park, S., Kwon, S. H., Jeon, J. S., Han, D. C., 
& Noh, H. (2020). Impaired fasting glucose and 
development of  chronic kidney disease in a non-
diabetic population: a Mendelian randomisation study. 
BMJ Open Diabetes Research and Care, 8(1), e001395. 

Kovesdy, C. P. (2022). Epidemiology of  chronic kidney 
disease: an update 2022. Kidney international supplements, 
12(1), 7-11. 

Koye, D., Shaw, J., Reid, C., Atkins, R., Reutens, A., & 
Magliano, D. (2017). Incidence of  chronic kidney 
disease among people with diabetes: a systematic 
review of  observational studies. Diabetic Medicine, 
34(7), 887-901. 

Koye, D. N., Magliano, D. J., Nelson, R. G., & Pavkov, M. 

E. (2018). The global epidemiology of  diabetes and 
kidney disease. Advances in chronic kidney disease, 25(2), 
121-132. 

Kurzhagen, J., Dellepiane, S., Cantaluppi, V., & Rabb, H. 
(2020). AKI: an increasingly recognised risk factor 
for CKD development and progression. Journal of  
Nephrology, 33(6), 1171-1187. 

Lu, J., Ma, X., Zhang, L., Mo, Y., Lu, W., Zhu, W., Bao, 
Y., Jia, W., & Zhou, J. (2020). Glycemic variability 
modifies the relationship between time in range and 
haemoglobin A1c estimated from continuous glucose 
monitoring: a preliminary study. Diabetes Research and 
Clinical Practice, 161, 108032. 

Mayeda, L., Katz, R., Ahmad, I., Bansal, N., Batacchi, Z., 
Hirsch, I. B., Robinson, N., Trence, D. L., Zelnick, L., 
& de Boer, I. H. (2020). Glucose time in range and 
peripheral neuropathy in type 2 diabetes mellitus and 
chronic kidney disease. BMJ Open Diabetes Research and 
Care, 8(1), e000991. 

Miller, W. G., & Jones, G. R. (2018). Estimated glomerular 
filtration rate; laboratory implementation and current 
global status. Advances in Chronic Kidney Disease, 25(1), 
7-13. 

Ohishi, M. (2018). Hypertension with diabetes mellitus: 
physiology and pathology. Hypertension Research, 41(6), 
389-393. 

Oshima, M., Shimizu, M., Yamanouchi, M., Toyama, T., 
Hara, A., Furuichi, K., & Wada, T. (2021). Trajectories 
of  kidney function in diabetes: a clinicopathological 
update. Nature Reviews Nephrology, 17(11), 740-750. 

Parving, H.-H., Persson, F., & Rossing, P. (2015). 
Microalbuminuria: a parameter that has changed 
diabetes care. Diabetes Research and Clinical Practice, 
107(1), 1-8. 

Persson, F., & Rossing, P. (2018). Diagnosis of  diabetic 
kidney disease: state of  the art and future perspective. 
Kidney International Supplements, 8(1), 2-7. 

Peruchetti, D. B., Barahuna-Filho, P. F., Silva-Aguiar, R. 
P., Abreu, T. P., Takiya, C. M., Cheng, J., Pinheiro, 
A. A. S., Cebotaru, L., Guggino, W. B., & Caruso-
Neves, C. (2021). Megalin-mediated albumin 
endocytosis in renal proximal tubules is involved in 
the antiproteinuric effect of  angiotensin II type 1 
receptor blocker in a subclinical acute kidney injury 
animal model. Biochimica et Biophysica Acta (BBA)-
General Subjects, 1865(9), 129950. 

Porta, M. (2020). Diabetes in ancient times: the long and 
winding road to insulin. In Unveiling Diabetes-Historical 
Milestones in Diabetology 29, 1-13. Karger Publishers. 

Prasad, R. M., & Tikaria, R. (2022). Microalbuminuria. 
StatPearls Publishing, Treasure Island (FL). http://
europepmc.org/abstract/MED/33085402

Prevention, C. F. D. C. a. (2020). World Diabetes Day. 
https://www.cdc.gov/globalhealth/infographics/
diabetes/world-diabetes-day.html#:~:text=Today%20
415%20Million%20people%20worldwide,a%20
billion%20will%20have%20diabetes.

Raja, P., Maxwell, A. P., & Brazil, D. P. (2021). The 

https://journals.e-palli.com/home/index.php/ajcp


Pa
ge

 
14

https://journals.e-palli.com/home/index.php/ajcp

Am. J. Chem. Pharm. 2(2) 9-14, 2023

potential of  albuminuria as a biomarker of  diabetic 
complications. Cardiovascular drugs and therapy, 35, 455-
466. 

Rodrigues, B. T., Vangaveti, V. N., Urkude, R., Biros, E., 
& Malabu, U. H. (2022). Prevalence and risk factors 
of  lower limb amputations in patients with diabetic 
foot ulcers: a systematic review and meta-analysis. 
Diabetes & Metabolic Syndrome: clinical research & 
reviews, 102397. 

Romagnani, P., Remuzzi, G., Glassock, R., Levin, A., 
Jager, K. J., Tonelli, M., Massy, Z., Wanner, C., & 
Anders, H.-J. (2017). Chronic kidney disease. Nature 
Reviews Disease primers, 3(1), 1-24. 

Sagoo, M. K., & Gnudi, L. (2020). Diabetic nephropathy: 
an overview. Diabetic Nephropathy: Methods and 
Protocols, 3-7. 

Seino, Y., Kuwata, H., & Yabe, D. (2016). Incretin‐
based drugs for type 2 diabetes: focus on East Asian 
perspectives. Journal of  diabetes investigation, 7, 102-109. 

Shah, V. N., Snell-Bergeon, J. K., Demmitt, J. K., Joshee, P., 
Garcetti, R., Pyle, L., & Polsky, S. (2021). Relationship 
Between Time-in-Range, HbA1c, and the Glucose 
Management Indicator in Pregnancies Complicated 
by Type 1 Diabetes. Diabetes Technol Ther, 23(12), 783-
790. https://doi.org/10.1089/dia.2021.0093 

Sutherland, D. E., & Gruessner, R. W. (2020). History 
of  pancreas transplantation. In Transplantation, 
Bioengineering, and Regeneration of  the Endocrine 
Pancreas 5-27. Elsevier. 

Tong, L., & Adler, S. G. (2018). Diabetic kidney disease. 

Clinical Journal of  the American Society of  Nephrology, 
13(2), 335-338. 

Vigersky, R. A., & McMahon, C. (2019). The relationship 
of  haemoglobin A1C to time-in-range in patients 
with diabetes. Diabetes Technology & therapeutics, 21(2), 
81-85. 

Webster, A. C., Nagler, E. V., Morton, R. L., & Masson, P. 
(2017). Chronic kidney disease. The Lancet, 389(10075), 
1238-1252. 

Williams, J. K. Y. (2017). Management strategies for 
diabetic kidney disease and chronic kidney disease in 
diabetes. Nursing Clinics, 52(4), 575-587. 

Winocour, P. (2018). Diabetes and chronic kidney disease: 
an increasingly common multi‐morbid disease 
needing a paradigm shift in care. Diabetic Medicine, 
35(3), 300-305. 

Wright, E. E., Jr., Morgan, K., Fu, D. K., Wilkins, N., & 
Guffey, W. J. (2020). Time in Range: How to Measure 
It, How to Report It, and Its Practical Application 
in Clinical Decision-Making. Clin Diabetes, 38(5), 439-
448. https://doi.org/10.2337/cd20-0042 

Yoo, J. H., & Kim, J. H. (2020). Time in the range from 
continuous glucose monitoring: a novel metric for 
glycemic control. Diabetes & metabolism journal, 44(6), 
828-839. 

Yu, E. S., Hong, K., & Chun, B. C. (2020). Incidence and 
risk factors of  vascular complications in people with 
impaired fasting glucose: a national cohort study in 
Korea. Scientific Reports, 10(1), 19504. https://doi.
org/10.1038/s41598-020-76661-7 

https://journals.e-palli.com/home/index.php/ajcp

